ArticleGenome biology2026
Evaluating deconvolution methods using real bulk RNA-expression data for robust prognostic insights across cancer types.
Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DeOPUS: cellular deconvolution via optimized power-transformed unmixing with shrinkage.Briefings in bioinformatics · 2026Article
- Evaluating deconvolution methods using real bulk RNA-expression data for robust prognostic insights across cancer types.Genome biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDeconvolution of bulk RNA-expression data unlocks the cellular complexity of cancer, yet traditional pseudobulk benchmarks may not always be reliable in real-world settings where absolute cell proportions are unknown.
resultsHere, we introduce a novel real-data framework, leveraging 18 real bulk RNA-expression cohorts (5,891 samples) across nine cancer types to evaluate five deconvolution methods based on differentially proportioned (DP) and prognosis-related (PR) cell types. Across three innovative benchmark scenarios-consistency with scRNA-seq, reproducibility across cohorts, and reproducibility of prognostic relevance-ReCIDE and BayesPrism stand out as two robust deconvolution methods. Application of a pan-cancer analysis based on the deconvolution of TCGA cohorts identifies matrix cancer-associated fibroblasts (mCAF) as a prognostic marker with consistent effects across multiple cancers. Building on this finding, we find a prognostic indicator combining classical monocytes and mCAF cell proportions to be significant in five TCGA cohorts, which we further validate in five independent GEO cohorts.
conclusionsThis study broadens deconvolution benchmarking, offering actionable tools for precision oncology and guiding method selection for translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.